ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
A bill creating a new agency, the Biomedical Advanced R&D Authority, was passed by the House last week. The agency will be in the Department of Health & Human Services and will coordinate all federal biodefense work, including the discovery and production of vaccines against bioweapons such as anthrax. The bill (H.R. 5533) authorizes funding at $160 million annually for fiscal 2007 and 2008. As a complement to the 10-year, $5.6 billion Project Bioshield, the new agency will try to fill a gap in federal support for biodefense R&D by funding more of the time-consuming drug development process. This funding is needed because private companies have been reluctant to invest in new drugs and vaccines that might not be used. A similar bill is pending in the Senate (S. 3678) and is expected to be passed before the Senate adjourns.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter